DNA Test Lets 2 in 3 Breast Cancer Patients Skip Chemo

Millions of breast cancer patients worldwide can now avoid chemotherapy's brutal side effects without compromising their survival, according to a major international trial.

Scientists developed a DNA test called Prosigna that identifies which patients truly need chemotherapy and which can safely skip it. The test measures activity in 50 genes linked to breast cancer growth and calculates each patient's risk of the disease returning.

The study, led by University College London, tracked more than 4,000 newly diagnosed patients over age 40 across six countries including the UK, Australia, and Thailand. Two-thirds of participants received low-risk scores and were treated with hormone therapy alone instead of chemotherapy.

The results were remarkable. The five-year survival rate for those who skipped chemo reached 93.7%, compared to 94.9% for those who received it. That tiny difference means thousands could avoid the grueling treatment without sacrificing their chances of survival.

Chemotherapy causes devastating side effects including extreme fatigue, constant nausea, hair loss, weakened immunity, and fertility problems. For many patients, these treatments can feel as brutal as the disease itself.

Karen Bonham, a 64-year-old from Cardiff who participated in the trial, called the results "an immense relief" that feels "like Christmas." Thanks to the Prosigna test, she avoided chemotherapy and instead received eight years of radiotherapy and hormone therapy.

"Cancer diagnosis and treatment can be shocking," Bonham said. "It certainly propels you into a world of uncertainty. Life priorities realign. You simply want to survive."

The UK's National Health Service expects more than 5,000 patients annually could avoid chemotherapy based on these findings. That represents a massive shift toward personalized medicine that treats the tumor's biology rather than applying one-size-fits-all protocols.

Why This Inspires

This breakthrough represents everything modern medicine should be: smarter, kinder, and more personalized. For decades, doctors knew chemotherapy was overprescribed for breast cancer but lacked the tools to safely identify who could skip it.

Now science has delivered that tool. Patients facing the terrifying words "you have cancer" can receive treatment tailored to their specific tumor rather than endure toxic drugs they might not need.

Professor Rob Stein, the trial's chief investigator and breast oncology professor at UCL Cancer Institute, emphasized the significance. "These results mark an important and significant step toward more personalized treatment," he said. "For patients, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term side effects."

The findings will be presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Researchers note the findings currently apply to patients over 40, with results for younger patients still several years away.

For healthcare systems worldwide, this represents more efficient use of resources while delivering better patient experiences without compromising outcomes.